---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008072"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:00:35.330533+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M

## Summary
- Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.
- Company may offer and sell up to $250 million of common shares at-the-market on Nasdaq.
- Sales agents Jefferies and Stifel will receive up to 3.0% commission on gross proceeds.
- No minimum obligation to sell; program may be terminated by either party upon written notice.
- Shares sold under existing shelf registration statement (File No. 333-260010) and prospectus supplement.

## SEC filing metadata
- accession: 0001564590-22-008072
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/0001564590-22-008072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/xene-8k_20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008072
- JSON: https://secwatch.observer/filing/0001564590-22-008072.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.